Literature DB >> 24466549

Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease.

Hae-Ryong Kang1, Yong-Hoon Kwon1, Eun-Sun Yoo2, Kyung-Ha Ryu2, Ji Yoon Kim3, Heung-Sik Kim3, Hwang Min Kim4, Young-Ho Lee1.   

Abstract

BACKGROUND: Our aim was to investigate the clinical pattern of hemophagocytic lymphohistiocytosis following Kawasaki disease (HLH-KD), to enable differentiation of HLH from recurrent or refractory KD and facilitate early diagnosis.
METHODS: We performed a nationwide retrospective survey and reviewed the clinical characteristics of patients with HLH-KD, including the interval between KD and HLH, clinical and laboratory findings, treatment responses, and outcomes, and compared them with historical data for both diseases.
RESULTS: Twelve patients with HLH-KD, including 5 previously reported cases, were recruited. The median age was 6.5 years (range, 9 months-14.7 years). Eight patients were male and 4 were female. The median interval between the first episode of KD and the second visit with recurrent fever was 12 days (3-22 days). Of the 12 children, 2 were initially treated with intravenous IgG (IVIG) for recurrent KD when they presented at the hospital with recurrent fever. Eventually, 10 children received chemotherapy under an HLH protocol and 2 received supportive treatment. Two patients died of combined infections during chemotherapy, 1 was lost to follow up, and 9 remain alive. The overall survival rate at 4 years was 81.1% with a median follow up of 45.1 months.
CONCLUSION: A diagnosis of HLH-KD should be considered when symptoms similar to recurrent KD develop within 1 month of the first episode of KD. Our findings will help physicians differentiate between HLH and the recurrent form of KD.

Entities:  

Keywords:  Hemophagocytic lymphohistiocytosis; Kawasaki disease; Recurrent

Year:  2013        PMID: 24466549      PMCID: PMC3894383          DOI: 10.5045/br.2013.48.4.254

Source DB:  PubMed          Journal:  Blood Res        ISSN: 2287-979X


  17 in total

1.  Hemophagocytosis complicating Kawasaki disease.

Authors:  W al-Eid; A al-Jefri; S Bahabri; S al-Mayouf
Journal:  Pediatr Hematol Oncol       Date:  2000-06       Impact factor: 1.969

2.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

3.  Hemophagocytic lymphohistiocytosis (HLH) and related disorders.

Authors:  Alexandra H Filipovich
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

4.  Kawasaki disease followed by haemophagocytic syndrome.

Authors:  K Kaneko; K Takahashi; S Fujiwara; T Maruyama; K Obinata
Journal:  Eur J Pediatr       Date:  1998-07       Impact factor: 3.183

Review 5.  Kawasaki disease: infection, immunity and genetics.

Authors:  Chih-Lu Wang; Yu-Tsun Wu; Chieh-An Liu; Ho-Chang Kuo; Kuender D Yang
Journal:  Pediatr Infect Dis J       Date:  2005-11       Impact factor: 2.129

Review 6.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.

Authors:  R Mouy; J L Stephan; P Pillet; E Haddad; P Hubert; A M Prieur
Journal:  J Pediatr       Date:  1996-11       Impact factor: 4.406

7.  UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis.

Authors:  Hoi Soo Yoon; Hee-Jin Kim; Keon-Hee Yoo; Ki-Woong Sung; Hong-Hoe Koo; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn; Ji-Yoon Kim; Young-Tak Lim; Keun-Wook Bae; Ki-O Lee; Ji-Sook Shin; Seung-Tae Lee; Hae-Sun Chung; Sun-Hee Kim; Chan-Jeoung Park; Hyun-Sook Chi; Ho-Joon Im; Jong Jin Seo
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state.

Authors:  S Ohga; A Ooshima; J Fukushige; K Ueda
Journal:  Eur J Pediatr       Date:  1995-07       Impact factor: 3.183

Review 9.  Hemophagocytic syndrome after Kawasaki disease.

Authors:  Debra L Palazzi; Kenneth L McClain; Sheldon L Kaplan
Journal:  Pediatr Infect Dis J       Date:  2003-07       Impact factor: 2.129

10.  Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis.

Authors:  Ulf Titze; Gritta Janka; E Marion Schneider; Friedrich Prall; Dieter Haffner; Carl Friedrich Classen
Journal:  Pediatr Blood Cancer       Date:  2009-09       Impact factor: 3.167

View more
  7 in total

1.  Forme Fruste of HLH (haemophagocytic lymphohistiocytosis): diagnostic and therapeutic challenges.

Authors:  Susumu Inoue; Chetna Mangat; Yaseen Rafe'e; Mahesh Sharman
Journal:  BMJ Case Rep       Date:  2015-01-29

2.  High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.

Authors:  Ashley Shafferman; James D Birmingham; Randy Q Cron
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-11       Impact factor: 3.054

3.  Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide.

Authors:  Jung Eun Choi; Yujin Kwak; Jung Won Huh; Eun-Sun Yoo; Kyung-Ha Ryu; Sejung Sohn; Young Mi Hong
Journal:  Korean J Pediatr       Date:  2018-05-28

Review 4.  Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

Review 5.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

6.  Severe Recurrent Fever Episodes With Clinical Diagnosis of Hemophagocytic Lymphohistiocytosis, Incomplete Kawasaki Disease and Systemic-Onset Juvenile Idiopathic Arthritis: A Case Report and Literature Review.

Authors:  Hongkun Jiang; Zhiliang Yang
Journal:  Front Pediatr       Date:  2020-03-10       Impact factor: 3.418

7.  Importance of Serum Ferritin Level for Early Diagnosis and Differentiation in Patients with Kawasaki Disease with Macrophage Activation Syndrome.

Authors:  Da Eun Roh; Jung Eun Kwon; Hee Joung Choi; Yeo Hyang Kim
Journal:  Children (Basel)       Date:  2021-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.